Shyam Sundar Selected Research

Paromomycin (Paromomycin Sulfate)

11/2021	Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients.
1/2020	Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis.
1/2019	Current and emerging medications for the treatment of leishmaniasis.
1/2014	Efficacy and Safety of Paromomycin in Treatment of Post-Kala-Azar Dermal Leishmaniasis.
3/2012	Recent advances in the diagnosis and treatment of kala-azar.
1/2012	Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol.
4/2011	Visceral leishmaniasis: elimination with existing interventions.
1/2011	Phase 4 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in India.
9/2009	Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment.
5/2008	Paromomycin in the treatment of leishmaniasis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shyam Sundar Research Topics

Disease

171	Visceral Leishmaniasis (Kala Azar) 08/2022 - 09/2002
40	Leishmaniasis 08/2022 - 12/2002
37	Infections 05/2022 - 10/2002
7	Neoplasms (Cancer) 10/2020 - 03/2008
6	Coinfection 01/2019 - 11/2008
5	Parasitic Diseases (Parasitic Disease) 01/2019 - 01/2012
5	Body Weight (Weight, Body) 04/2013 - 11/2002
4	Neglected Diseases 08/2022 - 01/2015
4	Inflammation (Inflammations) 01/2022 - 01/2016
4	Communicable Diseases (Infectious Diseases) 01/2021 - 01/2013
4	Fever (Fevers) 08/2016 - 06/2007
4	Acquired Immunodeficiency Syndrome (AIDS) 08/2016 - 01/2014
3	Asymptomatic Infections 01/2022 - 06/2012
3	Hypersensitivity (Allergy) 08/2016 - 01/2012
3	Malaria 07/2012 - 02/2008
3	Vomiting 06/2007 - 11/2002
2	Pain (Aches) 07/2020 - 06/2007
2	Papillomavirus Infections 12/2018 - 01/2016
2	Tuberculosis (Tuberculoses) 01/2014 - 02/2008
2	Cardiotoxicity 01/2014 - 12/2010
2	Anemia 01/2011 - 04/2004
2	Hemolysis 01/2011 - 04/2004
2	Cutaneous Leishmaniasis 04/2009 - 12/2002
2	Diarrhea 01/2004 - 11/2002
1	Protozoan Infections 01/2022
1	Cytokine Release Syndrome 01/2021
1	Chronic Disease (Chronic Diseases) 10/2020
1	Dry Socket (Alveolar Osteitis) 07/2020
1	Breast Neoplasms (Breast Cancer) 01/2020

Drug/Important Bio-Agent (IBA)

31	Pharmaceutical PreparationsIBA 01/2021 - 12/2002
29	miltefosine (Impavido)IBA 01/2019 - 11/2002
24	AntigensIBA 01/2021 - 08/2005
21	Proteins (Proteins, Gene)FDA Link 01/2022 - 08/2009
21	AntimonyIBA 01/2020 - 12/2002
19	Amphotericin B (Amphotericin)FDA LinkGeneric 08/2022 - 11/2002
19	VaccinesIBA 01/2022 - 12/2006
14	liposomal amphotericin B FDA Link 08/2022 - 12/2002
11	Paromomycin (Paromomycin Sulfate)FDA LinkGeneric 11/2021 - 06/2007
10	Interleukin-10 (Interleukin 10)IBA 01/2020 - 04/2007
8	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2008
7	CytokinesIBA 01/2018 - 01/2012
6	Immunoglobulin G (IgG)IBA 01/2019 - 05/2010
6	EnzymesIBA 01/2019 - 09/2004
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 06/2012
5	Messenger RNA (mRNA)IBA 04/2019 - 04/2007
5	Interleukin-12 (IL 12)IBA 01/2016 - 01/2012
5	deoxycholate drug combination amphotericin BIBA 01/2014 - 02/2004
4	N(1)-methyl-2-lysergic acid diethylamide (MIL)IBA 06/2017 - 01/2012
4	SodiumIBA 08/2015 - 08/2003
4	gluconic acid (gluconate)FDA LinkGeneric 08/2015 - 08/2003
4	Antimony Sodium Gluconate (Sodium, Stibogluconate)IBA 02/2015 - 06/2005
3	ChemokinesIBA 01/2021 - 10/2014
3	Imipramine (Janimine)FDA LinkGeneric 01/2020 - 01/2012
3	ImmunosorbentsIBA 01/2019 - 09/2004
3	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 07/2011
3	Interferon-gamma (Interferon, gamma)IBA 01/2018 - 04/2011
3	ArsenicIBA 03/2015 - 09/2011
3	18S Ribosomal RNAIBA 06/2012 - 10/2010
3	8-aminoquinolineIBA 06/2011 - 12/2002
2	AmphiregulinIBA 01/2022 - 01/2022
2	LigandsIBA 01/2022 - 08/2012
2	Biological ProductsIBA 08/2021 - 07/2012
2	Lipid NanoparticlesIBA 08/2021 - 01/2020
2	InterferonsIBA 01/2021 - 01/2019
2	ArginaseIBA 01/2020 - 04/2012
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2020 - 12/2017
2	CreatinineIBA 09/2019 - 09/2007
2	Peptides (Polypeptides)IBA 01/2019 - 09/2002
2	HLA-DRB1 Chains (HLA DRB1)IBA 01/2019 - 01/2018
2	tryparedoxin peroxidaseIBA 01/2018 - 04/2015
2	Interleukin-4 (Interleukin 4)IBA 01/2018 - 01/2012
2	LipidsIBA 01/2016 - 02/2004
2	trypanothione reductaseIBA 01/2015 - 03/2014
2	Sulfhydryl Compounds (Thiols)IBA 12/2014 - 01/2006
2	EmulsionsIBA 09/2014 - 08/2011
2	Fluconazole (Zonal)FDA LinkGeneric 01/2014 - 12/2002
2	Protein Disulfide-IsomerasesIBA 01/2014 - 01/2012
2	AntibodiesIBA 12/2013 - 02/2011
2	leishmaninIBA 11/2011 - 04/2009
2	InsecticidesIBA 12/2010 - 08/2008
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 06/2007 - 01/2004
1	Antiparasitic Agents (Antiparasitics)IBA 08/2022
1	febrifugineIBA 05/2022
1	Growth Factor ReceptorsIBA 01/2022
1	MelatoninIBA 08/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	spearmint oil drug combinations iodoform eugenol butyl aminobenzoateIBA 07/2020
1	Ointments (Pastes)IBA 07/2020
1	ELAV-Like Protein 1IBA 01/2020
1	Interferon Type IIBA 01/2020
1	Tricyclic Antidepressive Agents (Tricyclic Antidepressants)IBA 01/2020

Therapy/Procedure

28	Therapeutics 10/2020 - 12/2002
7	Aftercare (After-Treatment) 02/2021 - 01/2004
6	Drug Therapy (Chemotherapy) 02/2015 - 02/2009
4	Duration of Therapy 01/2018 - 02/2011
3	Immunotherapy 01/2017 - 01/2014
3	Art Therapy 07/2016 - 11/2015
2	Oral Administration 08/2021 - 02/2011
2	Conservative Treatment 09/2011 - 04/2011
2	Injections 06/2007 - 11/2002